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Abstract
Tumor hypoxia is one of the features of tumor microenvironment that contributes to chemoresistance in particular
by cellular adaptations that modulate the apoptotic process. However, the mechanisms involved in this resistance
still need deeper understanding. In this study, we investigated the involvement of four transcription factors, c-Myc,
nuclear factor κB (NF-κB), p53, and c-jun/activator protein 1 (AP-1) in the hypoxia-induced resistance to etoposide in
HepG2 cells. Whereas the profile of c-Myc and NF-κB activity did not fit the effect of hypoxia on caspase 3 activity,
hypoxia decreased basal p53 abundance and DNA binding activity as well as p53 etoposide-induced activation.
Short interfering RNA (siRNA) silencing evidenced that p53 was required for etoposide-induced apoptosis under
normoxia. An inhibition of its activity under hypoxia could thus be responsible at least in part for the protection
observed under hypoxic conditions. Moreover, p53 was found to induce the expression of Bak1. We showed that
Bak1 was involved in the etoposide-induced apoptosis because Bak1 siRNA decreased it. Conversely, hypoxia
increased c-jun DNA binding activity in the presence of etoposide. siRNA-mediated silencing of c-jun increased the
responsiveness of cells to etoposide under hypoxia, as shown by an increase in caspase 3 activity and lactate
dehydrogenase release. These effects occurred in a p53-independent manner. These data evidenced that hypoxia
decreased the responsiveness of HepG2 cells to etoposide at least by two independent pathways involving p53
inhibition and c-jun activation.
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Introduction
Tumor hypoxia is present in most solid tumors because of the abnor-
mal vascular network and the high cancer cell proliferation rate. Two
types of hypoxia are described: transient hypoxia and chronic hypoxia.
Transient hypoxia is a consequence of abnormal vasculature network
and high interstitial pressure that cause inadequate blood flow. In con-
trast, chronic hypoxia is caused by increased oxygen diffusion distance
due to tumor expansion. Chronic hypoxia affects tumor area at a dis-
tance greater than 70 to 100 μm from the nearest capillary [1]. Besides
its influence on the delivery and the uptake of chemotherapeutic drugs,
hypoxia also affects the responsiveness of cancer cells to chemotherapy
by inducing cellular adaptations through posttranslationalmodifications
and gene expression regulation [2]. Hypoxia promotes angiogenesis,
glucose transport, and anaerobic metabolism, invasion, resistance, and
survival particularly bymodulating the apoptotic process. Themain tran-
scription factor involved in the adaptation to hypoxia is the hypoxia-
inducible factor 1 (HIF-1). HIF-1 plays a role in the hypoxia-induced
metabolic switch, in the regulation of tumor pH, in triggering angiogene-
sis, and in the regulation of apoptotic process. Besides HIF-1, hypoxia
can modulate the activity of other transcription factors, among them
are nuclear factor κB (NF-κB), p53, c-myc, c-jun, ETS-1, Egr-1, or
SP-1 [3,4]. Some of them have been described to be involved in the
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down-regulation of apoptosis. Indeed, NF-κB regulates the expression
of antiapoptotic effectors such as Bcl-2, Bcl-xL, c-IAP2, or A1/Bfl1. In
contrast, p53 is able to induce apoptosis in response to various stresses
through its transcriptional activity and by direct interaction with Bcl-2
family members [5]. Some transcription factors can also be proapoptotic
or antiapoptotic according to the stress or the cell line. It is the case of
c-jun, a component of the transcription factor activator protein 1 (AP-1).
c-jun can regulate pathways leading either to apoptosis or to cell survival
and proliferation. For example, c-jun −/− fibroblasts have been shown
to be more resistant to UV irradiation [6]. In contrast, a protective role
of c-jun has been observed in T98G glioblastoma cells in response to
DNA-damaging agents such as cisplatin or etoposide but not in response
to thapsigargin or taxol [7].
Our previous studies have shown that hypoxia protects human hepa-
toma cell line HepG2 from DNA damage–induced apoptosis [8–10].
Etoposide, a topoisomerase II inhibitor, was used to induce double-
strand breaks in DNA. In this study, we investigated the involvement
of different hypoxia- or DNA damage–responsive transcription factors,
c-myc, NF-κB, p53, and c-jun in the hypoxia-induced resistance to
etoposide. We observed that hypoxia decreased the responsiveness of
HepG2 to etoposide by regulating p53 abundance and c-junDNAbind-
ing activity.
Materials and Methods
Cell Culture and Hypoxia Incubation
Human hepatoma cells HepG2 were maintained in culture in
75-cm2 polystyrene flasks (Costar, New York, NY) with 15 ml of
Dulbecco’s modified Eagle medium liquid and 10% of fetal calf serum
and incubated under an atmosphere containing 5% CO2. For hyp-
oxia experiments (1% O2), cells were incubated in serum-free CO2-
independent medium (Invitrogen, Carlsbad, CA) supplemented with
1 mM L-glutamine (Sigma, St. Louis, MO) with or without etoposide
(Sigma) at 50 μM. Normoxic control cells were incubated in the same
conditions but in normal atmosphere (21% O2).
Lactate Dehydrogenase Release
Lactate dehydrogenase (LDH) release was measured with the cyto-
toxicity detection kit from RocheMolecular Biochemical (Indianapolis,
IN) according to the manufacturer’s protocol.
Caspase 3 Activity
The fluorogenic substrate Ac-DEVD-AFC was used to measure
caspase 3 activity according to Lozano et al. [11]. Cell extracts were
prepared as described by Wellington et al. [12]. Cells were seeded in
six-well plates (250,000 cells per well). The assay for caspase 3 activity
was performed according to Cosse et al. [8].
Western Blot Analysis
Cells, seeded in 25-cm2 flasks, were scrapped in 200 μl of lysis
buffer (40 mM Tris pH 7.5, 150 mM KCl, 1 mM EDTA, 1% Triton
X-100) containing a protease inhibitor mixture (« Complete » from
Roche Molecular Biochemicals; 1 tablet in 2 ml of H2O, added at a
1: 25 dilution) and phosphatase inhibitors (25 mM NaVO3, 250 mM
PNPP, 250 mM α-glycerophosphate, and 125 mM NaF, at a 1: 25 di-
lution). Western blot analysis was performed as described in Piret et al.
[9] using mouse anti–poly (ADP-ribose) polymerase 1 (PARP-1)mono-
clonal antibody (no. 556493; PharMingen, San Diego, CA), rabbit
anti–c-jun antibody (SC-1694; Santa Cruz, Santa Cruz, CA), mouse
anti-PTEN antibody (SC-7974; Santa Cruz), caspase 3 (nos. 9662
and 9664; Cell Signaling, Beverly, MA), and anti-Bak1 antibody
(no. 556382; PharMingen) were used at 1:5000 dilutions. Mouse anti-
p53 (8-224; Upstate, Temecula, CA) was used at a 1:10,000 dilution.
Membranes were reprobed with α-tubulin antibody (final dilution,
1:50,000; Sigma) or with β-actin antibody (final dilution, 1:50,000;
Sigma) for normalization.
DNA Binding Assay
Nuclear protein extractions in high-salt buffer were prepared as
previously described [8]. DNA binding assays using TransAM ELISA
kit (Active Motif, Carlsbad, CA) for detecting transcription fac-
tor DNA binding activity was performed according to the manufac-
turer’s recommendations.
Gene Expression Analysis on DNA Microarray
We used a low-density DNA array allowing the gene expression analy-
sis for 123 genes related to apoptosis (DualChip Human Apoptosis;
Eppendorf, Hamburg, Germany).HepG2 cells cultured in 75-cm2 flasks
(Corning, New York, NY) were incubated for 16 hours with or without
etoposide under normoxic and hypoxic conditions. At the end of the
incubation, total RNA was extracted with the TRIzol Extraction Kit
(Invitrogen), quality was checked with a bioanalyzer (Agilent Technolo-
gies, Waldbronn, Germany), and 25 μg was used for retrotranscription
in the presence of biotin-11-dCTP (Perkin-Elmer, Boston, MA) and
SuperScript II Reverse Transcriptase (Invitrogen), as described previously
[13]. Hybridizations on the arrays were carried out as described by the
manufacturer. Detection was performed with a cyanin 3–conjugated
immunoglobulin antibiotin (Jackson ImmunoResearch Laboratories,
West Grove, PA). Fluorescence of hybridized arrays was scanned using
a Packard ScanArray (Perkin-Elmer) at a resolution of 10 μm.
Real-time Reverse Transcription–Polymerase Chain Reaction
After the incubation, total RNA was extracted using the TRIzol Ex-
traction Kit (Invitrogen). Messenger RNA (mRNA) contained in 2 μg
of total RNAwas reverse-transcribed using SuperScript II Reverse Tran-
scriptase (Invitrogen) according to the manufacturer’s instructions. For-
ward and reverse primers for Bak1, PUMA, CDKN1A, c-jun, p53, and
RPL13A were designed using the Primer Express 1.5 software (Applied
Biosystems, Cheschire, UK). Amplification reaction assays contained
1× SYBR Green PCR Mastermix (Applied Biosystems) and primers
(Eurogentec, Seraing, Belgium) at the optimal concentrations. RPL13A
was used as the reference gene for normalization, and mRNA expression
level was quantified using the threshold cycle method.
Short Interfering RNA Transfection
The siGENOME smartpool of short interfering RNA (siRNA)
anti-p53 (M-003329-01), anti-Bak1 (M-003305-01), and anti–c-jun
(M-003268-02) were obtained from Dharmacon (Lafayette, CO).
The siGENOME smartpool of siRNA was transfected with the
DharmaFECT1 transfection reagent (T-2001; Dharmacon) according
to the manufacturer’s recommendations. Cells seeded at 40,000 cells/
cm2 were incubated with transfection medium for 24 hours. After
this incubation, transfection medium was replaced by fresh medium
with 10% of fetal calf serum. DharmaFECT1 was used at a final di-
lution equal to 1:500, and siRNA were used at 50 nM. siCONTROL
Nontargeting no. 1 (D-001210-01) and siCONTROL RISC free
(D-001220-01) siRNA were used as negative controls.
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Results
Effect of Hypoxia and/or Etoposide on the DNA Binding
Activity of p53, c-jun, c-myc, and NF-κB
To determine the involvement of c-myc, NF-κB, p53, and c-jun in
the protection of HepG2 cells by hypoxia, we compared the etoposide-
induced caspase 3 activity with the DNA binding activity of these tran-
scription factors for increasing periods from 2 to 16 hours of incubation
with or without etoposide under normoxia or under hypoxia. What we
called “normoxia” in standard culture conditions is not the physiologi-
cal oxygen pressure that cells encounter within organs and tissues. Rele-
vant physiological oxygen pressure ranges from 10% to 3% oxygen. In
these conditions, both in vivo and in vitro, HIF-1 is not active, and
there is no detectable HIF-1α protein. That is the case for most normal
human tissues. However, in tumors, including the ones in liver, a true
hypoxia can occur due to the oxygen diffusion limit as well as to the dys-
functioning tumor blood vessels. In this case, the oxygen pressure falls to
values less than 1%, and HIF-1α is stabilized. In this work, we used
in vitro conditions that mimic the “true” hypoxia that occurs in tumors.
Indeed, HIF-1 has been shown to be activated in these conditions [10].
As a first step, the effect of hypoxia on the etoposide-induced apop-
tosis was studied by following the abundance of active caspase 3 and
its activity. For an incubation time longer than 8 hours with etoposide,
we observed an accumulation of the active caspase 3 and the cleavage of
PARP, an endogenous substrate of caspase 3 by Western blot (Figure 1,
C and D). Neither the active caspase 3 nor the cleaved form of PARP
is observed during the first 8 hours of incubation with etoposide.
However, the etoposide-induced activity of caspase 3 was detected from
8 hours of incubation using a more sensitive method based on the
cleavage of a specific fluorogenic substrate Ac-DEVD-AFC (Figure 1A).
Figure 1. Effect of hypoxia and/or etoposide on caspase 3 activity and p53 regulation. HepG2 cells were incubated under normoxic (Nx;
21% O2) or hypoxic (Hx; 1% O2) conditions with (Ne-He; 50 μM) or without etoposide (Nx-Hx) for increasing periods from 2 to 16 hours
or from 2 to 24 hours. (A) Caspase 3 activity was assayed by measuring fluorescence intensity associated to free AFC released from the
cleavage of caspase 3 substrate Ac-DEVD-AFC. Data are expressed in percentages of caspase 3 activity in control cells (Nx) as means ±
1 SD (n = 3). (B) p53 DNA binding activity was assessed by colorimetric assay. Data are expressed in percentage of DNA binding in
control cells (Nx) and correspond to the mean value ± 1 SD from three independent experiments. (C and D) PARP-1, caspase 3 (CASP3),
and p53 were detected in total cell extracts by Western blot analysis, using specific antibody. α-Tubulin and β-actin were used to assess
the total amount of proteins loaded on the gel. t0 = time zero.
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Hypoxia per se had no effect on caspase 3 activity but inhibited the effect
of etoposide on the caspase 3 activity as soon as its activity was detected.
Etoposide induced the stabilization and the DNA binding activity of
p53 already after 2 hours of incubation (Figure 1, B andD). The DNA
binding activity of p53 continued to rise up to 4 hours of incubation.
For longer incubation periods, the DNA binding activity remained
constant. Hypoxia led to a decrease in the etoposide-induced increase
in p53 abundance and in its DNA binding activity, which was more
important for longer incubation periods. In addition, hypoxia by itself
decreased p53 abundance and its DNA binding activity (Figure 1C ).
Because p53 is a proapoptotic factor, the regulation of p53 by hypoxia
could be one of the causes of cell resistance to etoposide-induced apop-
tosis in these conditions.
We observed that c-myc DNA binding activity decreased over time
for all conditions, and this effect was amplified when cells were incu-
bated in the presence of etoposide and/or under hypoxia (Figure 2A).
The absence of serum during the incubation could possibly explain
this decrease. The DNA binding activity of NF-κB (p65) was already
increased by etoposide from 2 hours of incubation, regardless of the
PO2 (Figure 2B). No differential effect according the PO2 was observed
on the etoposide-induced DNA binding of NF-κB before the onset of
the effect of hypoxia on the etoposide-induced caspase 3 activity. There-
fore, we also ruled out a participation of NF-κB.
Differences in c-jun DNA binding activity according to conditions
were also observed. TheDNAbinding activity of c-jun was not modified
by etoposide alone or by hypoxia alone. However, etoposide increased
the DNA binding activity of c-jun under hypoxia already after 4 hours
of incubation (Figure 2C). Therefore, the increase in c-jun DNA bind-
ing activity might be required for the hypoxia-induced resistance to
etoposide. According to these data, we decided to investigate the involve-
ment of p53 and c-jun in the hypoxia-induced resistance to etoposide.
Effect of p53 Silencing on the Etoposide-Induced Apoptosis
Hypoxia decreased p53 stabilization as well as p53 DNA binding
activity. DNA damage–like double-strand break induced the stabiliza-
tion and the activation of p53 through posttranslational modifications.
Thereafter, p53 contributes to induce cell cycle arrest or apoptosis [14].
We observed that etoposide induced the stabilization and the activation
of p53. Hypoxia could therefore protect HepG2 cells to etoposide-
induced apoptosis by down-regulating p53. To evidence a putative role
Figure 2. Effect of hypoxia and/or etoposide on the DNA binding activity of c-myc, NF-κB, and c-jun. HepG2 cells were incubated under
normoxic (Nx; 21% O2) or hypoxic (Hx; 1% O2) conditions with (Ne-He; 50 μM) or without etoposide (Nx-Hx) for increasing periods from
2 to 16 hours. The DNA binding activity of c-myc (A), NF-κB (B), or c-jun (C) was assessed by a colorimetric assay. Data are expressed in
percentage of DNA binding in control cells (Nx) and correspond to the mean value ± 1 SD from three independent experiments.
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of p53 in the etoposide-induced apoptosis and in its modulation by
hypoxia, we inhibited p53 expression using specific siRNA. Cells were
transfected with siRNA targeting p53 or negative control siRNA during
24 hours. At the end of the transfection, transfection medium was re-
placed by fresh medium. Twenty-four hours after the end of the trans-
fection, p53 mRNA and protein levels were assessed. The knock down
of p53 by an siRNA smartpool at a final concentration of 50 nM
reached more than 80% at both levels (Figure W1). The consequence
of p53 silencing on apoptosis and cell death was then investigated by
following the activity of caspase 3 and LDH release, respectively.HepG2
cells were incubated during 16 hours with or without etoposide under
normoxia or under hypoxia. Caspase 3 activity was assayed using fluoro-
genic substrate Ac-DEVD-AFC and by following the cleavage of one of
its main endogenous substrates, PARP-1 (Figure 3, A and B). Hypoxia
inhibited the effect of etoposide on the activity of caspase 3 and had little
effect per se in the absence of etoposide. Under normoxia, p53 siRNA
inhibited the etoposide-induced caspase 3 activity as well as PARP-1
cleavage but had no effect on caspase 3 activity when cells were in-
cubated without etoposide. Neither etoposide nor siRNA influenced
caspase 3 activity under hypoxia, whereas hypoxia per se slightly de-
creased caspase 3 activity. Negative control siRNA had little or no
effect on caspase 3 activity and PARP-1 cleavage whatever the conditions.
To assay cell death, LDH release was measured after 40 hours of incu-
bation. Etoposide strongly increased the LDH release under normoxia
and, to a lesser extent, under hypoxia (Figure 3C ). Under normoxia,
p53 siRNA reduced by 50% the etoposide-induced LDH, whereas neg-
ative control siRNA had no effect. Hypoxia did not influence LDH re-
lease, and p53 siRNA had very limited effect on etoposide-induced
LDH release under hypoxia compared with that observed under
normoxia. All together, these results indicated that p53 was necessary
Figure 3. Effect of p53 silencing on etoposide-induced apoptosis. HepG2 cells were transfected with 50 nM p53 siRNA or negative control
siRNA for 24 hours. Eight hours later, cells were incubated under normoxic (Nx) or hypoxic (Hx) conditionswith (Ne-He) or without etoposide
(Nx-Hx) for 16 hours (A, B, D) or 40 hours (C). (A) Caspase 3 activity was assayed by measuring fluorescence intensity associated to free
AFC released from the cleavage of the caspase 3 substrate Ac-DEVD-AFC. Results are normalized by fluorescence intensity of control cells
(Nx) and are expressed in percentages as means ± 1 SD (n = 3). (B) Total extracts were analyzed by Western blot analysis for PARP-1 and
cleaved 85-kDa fragment using a specific anti–PARP-1 antibody. p53 protein level was assessed using specific anti-p53 antibody, and
α-tubulin was used to assess the total amount of proteins loaded on the gel. (C) LDH release was assessed after 40 hours of incubation.
Results are normalized by the LDH release of control cells and are presented in percentages as means ± 1 SD (n = 3). (D) Effect of p53
silencing on cell cycle and apoptosis-related genes expression. Biotinylated complementary DNA were generated by reverse transcription
and hybridized on DualChip microarray as described in the Materials and Methods section. Data are logarithm base 2 of the mean of three
ratio values calculated from three independent experiments. Data are presented on a tree obtained by applying a hierarchical clustering
method (metric = Pearson correlation; method = complete linkage) to the expression data. Statistical analysis was carried out with the
Student’s t test. ns indicates nonsignificant; * .05 > P > .01; ** .01 > P > .001; ***P < .001.
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for etoposide-induced apoptosis and cell death under normoxia. More-
over, the effect of p53 siRNA on etoposide-induced apoptosis under
normoxia was very similar to the one of hypoxia.
Effect of p53 Silencing on Gene Expression
To better understand the role of p53 on the etoposide-induced
apoptosis, we assessed the effect of p53 silencing on the mRNA level
of genes encoding proteins involved in the regulation of apoptosis pro-
cess using a low-density DNAmicroarray. The level of several transcripts
was increased after incubation in the presence of etoposide. Etoposide-
induced genes could be divided into two categories: the genes that are
expressed in a p53-dependent manner and the others. Unlike AKT1,
CCND1, or DFFA, the expression of some genes was dependent on
the presence of p53 because they were not induced by etoposide in cells
transfected with p53 siRNA. Among them were well-known p53 tar-
get genes such as CDKN1A [15], MDM2 [16], Bax [17], PCNA [18],
IGFBP2 [19], GPX1 [20], TNFRSF10B [21], and GADD45A [22]
(Figure 3D). Moreover, Bak1, encoding a proapoptotic protein, dis-
played an expression profile that was similar to the one of p53 target
genes. These data suggested that Bak1 could be a p53 target gene. Con-
versely, IGF1R seemed to be negatively regulated by p53 because it was
downregulated by etoposide and upregulated if p53 was absent because
of p53 siRNA or under hypoxia. Overall, the negative control siRNA
had little or no effect on the expression of genes studied regardless of
the condition. Hypoxia reduced the expression of p53 target genes and
Bak1 even if they were induced by etoposide. Among the etoposide-
induced genes in a p53-independent manner, some of them were also
downregulated by hypoxia such as CDC2, whereas others such as
CCND1, DFFA, and Bid were not. Hypoxia per se affected the expres-
sion of some genes: CDC6, BAG1, Jun, and BNIP3 were upregulated,
whereas RBL2 and TFRC were downregulated. The efficiency of p53
siRNA was confirmed by the sharp decline of p53 mRNA level after
transfection with p53 siRNA, whereas negative control siRNA had no
effect. Moreover, if etoposide induced a slight increase in p53 mRNA
level, it was not affected by hypoxia. The fact that our data are in good
agreement with previous studies reporting modifications in hypoxia-
responsive genes (BNIP3, JUN [23]) during hypoxia as well as in p53
target genes (CDKN1A,Bax,Gadd45A, etc.) in the presence of etoposide
already validates the DNA microarray used in this study. The data ob-
tained for Bak (Figure 4A) as well as for other genes (data not shown)
were confirmed by SYBR Green quantitative real-time polymerase
chain reaction. To study whether the modulation of BakmRNAwas also
Figure 4. Effect of p53 silencing on Bak1 expression and effect of Bak1 silencing on the etoposide-induced apoptosis. HepG2 cells were
transfected with 50 nMBak1 siRNA, 50 nM p53 siRNA, or negative control siRNA for 24 hours. Eight hours later, cells were incubated under
normoxic (Nx; 21%O2) or hypoxic (Hx; 1%O2) conditionswith (Ne-He; 50 μM) orwithout etoposide (Nx-Hx) for 16 hours (A, B, C) or 40 hours
(D). The effect of p53 silencing on Bak mRNAwas confirmed by real-time reverse transcription–polymerase chain reaction (A), and the Bak1
protein level was assessed by Western blot using a specific antibody (B). α-Tubulin was used to assess the total amount of proteins loaded
on the gel. One experiment of two independent ones is shown here (A, B). The effect of Bak1 silencing on the etoposide-induced apoptosis
was assessed by measuring the caspase 3 activity (C) and the LDH release (D). (C) Caspase 3 activity was assayed by measuring fluores-
cence intensity associated to free AFC released from the cleavage of the caspase 3 substrate Ac-DEVD-AFC. Results are normalized by
fluorescence intensity of control cells (Nx) and are expressed in percentages as means ± 1 SD (n= 3). (D) LDH release was assessed after
40 hours of incubation. Results are presented in percentages asmeans± 1 SD (n=3). Statistical analysis was carried out with the Student’s
t test. ns indicates nonsignificant; * .05 > P > .01; ** .01 > P > .001; ***P < .001.
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observed at the protein level, the abundance of Bak was assessed by
Western blot analysis. We observed that there was a very good correla-
tion between mRNA and protein levels: etoposide increased Bak1 pro-
tein andmRNA levels under normoxia, whereas hypoxia and p53 siRNA
inhibited the effect of etoposide (Figure 4B). In addition, hypoxia de-
creased Bak level. According to these results, we postulated that Bak is
a protein by which p53 can induce apoptosis in response to etoposide.
Effect of Bak Silencing on the Etoposide-Induced Apoptosis
To study the involvement of Bak in the etoposide-induced apop-
tosis through a p53-dependant pathway under normoxia, Bak expres-
sion was silenced through RNA interference. Bak protein and mRNA
levels were reduced to less than 20% when Bak siRNA was transfected
(Figure W2). To evaluate caspase 3 activity, cells were incubated with
or without etoposide under normoxia or hypoxia during 16 hours. Bak
siRNA decreased by more than 50% the etoposide-induced caspase 3
activity under normoxia, whereas negative control siRNA had no effect
(Figure 4C ). Under hypoxia, the etoposide-induced caspase 3 activity
was much lower than under normoxia and was not affected by Bak
siRNA. The abundance of cleaved PARP-1 was investigated to confirm
the results. Under normoxia, Bak siRNA reduced the etoposide-
induced PARP-1 cleavage, whereas negative control siRNA had no ef-
fect (data not shown). To determine the effects of Bak siRNA on cell
viability, LDH release was investigated after 40 hours of incubation.
Bak siRNA decreased by 20% the etoposide-induced LDH release
under normoxia, whereas negative control siRNA had no effect (Fig-
ure 4D). The etoposide-induced LDH release was strongly inhibited
under hypoxia. Under hypoxia, Bak siRNA had very limited effects
in comparison to negative control siRNA. On the basis of these data,
we concluded that Bak may be involved in the etoposide-induced
apoptosis under normoxia but did not seem to be the only one protein
involved because the effect of Bak1 siRNA was only partial.
Effect of c-jun Silencing on the Etoposide-Induced Apoptosis
As shown in Figure 2C , incubation of cells under hypoxia in the
presence of etoposide increased c-jun DNA binding activity. To de-
termine if c-jun was implicated in the hypoxia-induced resistance to
etoposide, we inhibited its expression using siRNA.We observed a lower
silencing effect of c-jun siRNA than for other siRNA used (Figure W3):
a decrease of 50% was observed at the mRNA level. However, this de-
crease was sufficient to obtain a significant decrease at the protein level.
In addition, a larger decrease of the mRNA level was observed when
c-jun expression was induced by hypoxia. To evaluate the effect of
c-jun silencing on the etoposide-induced apoptosis and its modulation
by hypoxia, cells were incubated with or without etoposide under
normoxia or hypoxia during 16 hours. Under normoxia, c-jun siRNA
did not influence the effect of etoposide on caspase 3 as observed by
following the abundance of active caspase 3 studied by Western blot
and on its activity measured by the cleavage of fluorogenic substrate
Ac-DEVD-AFC and by following the cleavage of PARP-1 by Western
blot (Figure 5, A–C). In addition, c-jun silencing had no consequence
on etoposide-induced cell death as revealed by LDH release under
normoxia when cells were incubated for 40 hours in the presence of
etoposide (Figure 5D). Contrary to what was observed under normoxia,
c-jun silencing partially relieved hypoxia-induced resistance to etoposide.
Indeed, c-jun siRNA led to an increase in the abundance of active
caspase 3. Moreover, the etoposide-induced cleavage of PARP and Ac-
DEVD-AFC were higher in cells transfected with siRNA c-jun than in
nontransfected cells in response to etoposide. These data were confirmed
by LDH release assay after 40 hours of incubation: an increase in LDH
release was observed in transfected cells (Figure 5D). Negative control
siRNA had no effect neither on caspase 3 abundance and activity nor
on LDH release. Together, these data indicate that c-jun was not involved
in the etoposide-induced apoptosis but was required for the hypoxia-
induced resistance to etoposide-induced apoptosis.
In an attempt to understand the role of c-jun in the hypoxia-induced
resistance to etoposide, we considered the involvement of several mech-
anisms. Hettinger et al. [24] highlighted that c-jun promoted cellular
survival by negatively regulating the expression of PTEN, resulting
in the concomitant activation of Akt survival pathway. To determine
whether c-jun was involved in the regulation of PTEN in this model,
PTEN protein level was assessed. PTEN protein level was not affected
by etoposide neither under normoxia nor under hypoxia (Figure 6C).
In contrast, hypoxia per se significantly reduced protein level. Neither
c-jun siRNA nor negative control siRNA affected PTEN level, what-
ever the oxygen concentration.
The preventive effect of c-jun over cell death by suppression of p53 has
been highlighted by Eferl et al. [25]. To study the effect of c-jun on the
regulation of p53, the effect of c-jun silencing on the p53 mRNA and
protein levels was investigated. The etoposide-induced stabilization of
p53 under normoxia and reduced abundance of p53 under hypoxia were
not influenced by the inhibition of the expression of c-jun (Figure 6C).
The inhibition of the expression of c-jun did not alter the mRNA level of
p53 (data not shown). In addition, the p53 silencing did not influence
the expression of p53 target genes, as shown for CDKN1A and PUMA
(Figure 6A). We have shown previously that the expression of Bak was
similar to the expression of p53 target genes. We observed that the ex-
pression of Bak was not influenced by inhibiting the expression of c-jun
(Figure 6B). Therefore, the involvement of c-jun in the hypoxia-induced
resistance to etoposide is independent of p53.
Discussion
Cell adaptation to hypoxia is largely mediated by gene expression reg-
ulation through the activation of HIF-1. Numerous reports showed
that HIF-1 is closely linked to positive and negative regulation of the
apoptotic process [26–29]. However, HIF-1–independent regulations
of apoptosis by hypoxia have also been described [15,27,30,31]. Be-
sides HIF-1, numerous transcription factors also respond to hypoxia;
among them are NF-κB, p53, c-jun, c-myc, ETS-1, Egr-1, or SP-1
[3]. In this study, we investigated the involvement of four of them,
namely, c-Myc, NF-κB, p53, and c-jun/AP-1, in the hypoxia-induced
resistance to etoposide in HepG2 cells.
The myc protein is a transcription factor that regulates cellular
processes including cell growth, proliferation, differentiation, and apop-
tosis. c-Myc is able to induce apoptosis by the activation of the ARF-
MDM2-p53 axis [32]. In addition, c-Myc regulates the balance between
proapoptotic and antiapoptotic members of Bcl-2 family by inducing the
expression of Bax and the repression of Bcl-2 and Bcl-XL [33–35]. Under
hypoxia, cooperation of c-myc with HIF-1 contributes to angiogenesis
and to the metabolic switch [4]. However, the results of this work suggest
that c-myc is not involved in the regulation of etoposide-induced apop-
tosis by hypoxia in HepG2 cells. If c-Myc DNA binding activity was
modified by etoposide and serum deprivation, hypoxia had no effect.
Similarly, NF-κB, which favors cell survival by increasing the expres-
sion of antiapoptotic genes such as IAPs, was not a good candidate be-
cause the effect of hypoxia on NF-κB occurred much later than its
inhibiting effect on caspase 3 activity. In contrast, p53 DNA binding
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activity and protein level were downregulated by hypoxia, and c-jun
DNA binding was increased when cells were incubated in the presence
of etoposide under hypoxia, both events occurring early during the in-
cubation under hypoxia.
We observed that etoposide induced the stabilization and the DNA
binding activity of p53. These data are coherent with the literature
because it was widely described that p53 is rapidly stabilized by a wide
array of cellular stresses such as oncogene-mediated hyperproliferation,
translation perturbation, or DNA damage. In case of genotoxic damage,
kinases belonging to PIKK family (ATM, ATR, DNA-PK) contribute
to the stabilization and the activation of p53 [36]. p53 may induce
DNA repair, cell cycle arrest, or apoptosis according to the nature of
stress and the extent of the damage. The regulation of apoptosis by
p53 occurs through the induction of genes encoding proapoptotic pro-
tein, such as Bax, Puma,Noxa, Fas, and FasL, and by a direct interaction
with members of the Bcl-2 family. We observed that hypoxia decreased
p53 abundance and p53 DNA binding activity and inhibited the ef-
fect of etoposide on its stability and its DNA binding activity. Numer-
ous reports have evidenced positive or negative regulation of p53 by
hypoxia according to the severity and the duration of hypoxia. Mild
hypoxia does not influence or even decreases p53 abundance. In
HepG2 cells, low abundance of p53 under mild hypoxia was explained
by CK2-mediated targeting of p53 for proteasomal degradation [37].
Conversely, severe or prolonged hypoxia leads to the stabilization of
p53 by an HIF-1–dependent pathway. In addition, differential effects
of hypoxia on the regulation of p53 according to the cell lines have been
described [8].
To test if the hypoxia-induced down-regulation of p53 contributes
to the resistance to etoposide, the expression of p53 was inhibited
using siRNA. We observed that p53 silencing desensitized HepG2 cells
to etoposide-induced apoptosis under normoxia. Indeed, caspase 3
activity and LDH release were significantly reduced by the knock down
of p53. These data indicated that p53 was required for etoposide-
induced apoptosis and supported the hypothesis that postulates that
hypoxia protects HepG2 cells against etoposide-induced apoptosis by
down-regulating p53. To delineate the mechanisms responsible for
the etoposide-induced apoptosis through p53, gene expression changes
were also studied. Unsurprisingly, we observed that p53 silencing affected
etoposide-induced known p53 target genes as CDKN1A, MDM2, Bax,
PCNA, IGFBP2, GPX1, TNFRSF10B, or GADD45A. However, Bak1
expression profile was similar to p53 target genes because it was up-
regulated by etoposide and downregulated by p53 silencing and hypoxia.
Figure 5. Effect of c-jun silencing on hypoxia-induced resistance to etoposide-induced apoptosis. HepG2 cells were transfected with 50 nM
c-jun siRNA or negative control siRNA for 24 hours. Eight hours later, cells were incubated under normoxic (Nx; 21% O2) or hypoxic (Hx;
1%O2) conditionswith (Ne-He; 50 μM) orwithout etoposide (Nx-Hx) for 16 hours (A, B, C) or 40 hours (D). (A) Caspase 3 activity was assayed
by measuring fluorescence intensity associated to free AFC released from the cleavage of the caspase 3 substrate Ac-DEVD-AFC. Results
are normalized by fluorescence intensity of control cells (Nx) and are expressed in percentages as means ± 1 SD (n = 3). (B and C) Total
extracts were analyzed by Western blot analysis for PARP-1 and active caspase 3 using specific anti–PARP-1 and active caspase 3 anti-
bodies. c-jun protein level was assessed using specific anti–c-jun antibody, and α-tubulin was used to assess the total amount of proteins
loaded on the gel. (D) LDH release was measured after 40 hours of incubation. Results are presented in percentages of LDH release
in control cells (Nx) as means ± 1 SD (n = 3). Statistical analysis was carried out with the Student’s t test. ns indicates nonsignificant;
* .05 > P > .01; ** .01 > P > .001; ***P < .001.
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This result indicates that Bak1 is induced by a p53-dependent mecha-
nism. Bak is proapoptotic protein of Bcl2 family that is permanently
embedded into the outermitochondrialmembrane. In response to apopto-
tic stimulus, Bak is activated by conformational change, which allows its
oligomerization in the outer mitochondrial membrane to induce the re-
lease of cytochrome c and other factors such as AIF and SMAC/DIABLO.
Because of these data, the involvement of Bak in the etoposide-induced
apoptosis was investigated. We observed that Bak silencing reduced
etoposide-induced caspase 3 activity and cytotoxicity. However, the Bak
silencing only had partial effect on the etoposide-induced apoptosis in
contrast to what was observed with p53 siRNA. So, it seemed that Bak
is involved in the etoposide-induced apoptosis but that other proteins
are probably also involved.
In addition, we observed that hypoxia induced the DNA binding
activity of c-jun when HepG2 cells were incubated in the presence
of etoposide. As the involvement of c-jun in the positive or negative
regulation of apoptosis was described, we investigated if the enhancing
of c-jun DNA binding activity contributed to the hypoxia-induced re-
sistance to etoposide. Our data indicate that c-jun was not involved in
the etoposide-induced apoptosis under normoxia. However, the c-jun
silencing relieved the hypoxia-induced resistance to etoposide as ob-
served by the increase in the activity of caspase 3 and in the LDH
release. These data indicate that c-jun is required for the hypoxia-
induced resistance to etoposide. Hettinger et al. [24] have shown that
c-jun can inhibit apoptosis through the repression of PTEN, allowing
the activation of the PI3K/AKTsurvival pathway in human cancer cells.
However, the abundance of PTEN was not affected by the silencing of
c-jun whatever the conditions. It must be noted that we observed a de-
crease in the abundance of PTEN under hypoxia. This decrease was
not affected by etoposide or by the transfection with siRNA. However,
it could be envisaged that the decrease in the abundance of PTEN is
favorable to the resistance of cancer cells to etoposide under hypoxia.
A negative regulation of p53 by c-jun has been highlighted by several
teams. Schreiber et al. [38] have demonstrated that c-jun represses the
expression of p53 by direct binding to a variant AP-1 site in the p53
promoter in 3T3 fibroblast. Conversely, an antagonizing effect of c-jun
on the p53 activity has been shown on mice hepatocytes by Eferl et al.
[25]. However, it was not the case in this model because the silencing
of c-jun did not influence the mRNA (data not shown) and the pro-
tein levels of p53 (Figure 6C). In addition, hypoxia did not decrease
the abundance of p53 mRNA unlike what is observed at the protein
level (Figure 3, B and D). The inhibition of the expression of c-jun
did not modify the transcriptional activity of p53 as observed on the
mRNA level of CDKN1A and PUMA (Figure 6A). In the same line,
Figure 6. Effect of c-jun silencing on hypoxia-induced resistance to etoposide-induced apoptosis. HepG2 cells were transfected with 50 nM
c-jun siRNAor negative control siRNA for 24hours. Eight hours later, cellswere incubated under normoxic (Nx; 21%O2) or hypoxic (Hx; 1%O2)
conditions with (Ne-He; 50 μM) or without etoposide (Nx-Hx) for 16 hours. (A and B) At the end of the incubation, total RNA was extracted,
submitted to reverse transcription, and then to amplification in the presence of SYBR Green and specific primers for CDKN1A and PUMA.
RPL13A was used as the housekeeping gene for data normalization. One experiment of two independent ones is shown here (A, B). (C) At
the same time, total extracts were prepared and analyzed by Western blot analysis for p53, PTEN, Bak1, and c-jun using specific antibodies.
α-Tubulin was used to assess the total amount of proteins loaded on the gel.
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the expression of Bak was not modified by the inhibition of the ex-
pression of c-jun (Figure 6B). These data indicate that the silencing
of c-jun did not allow to restore, under hypoxia, the pathway by which
etoposide induced apoptosis under normoxia. Therefore, the silencing
of c-jun allowed the etoposide-induced apoptosis by a p53-independent
pathway under hypoxia.
In conclusion, we showed that hypoxia protected HepG2 cells from
etoposide-induced apoptosis by two independent pathways: the de-
crease in p53 abundance and the increase in c-jun DNA binding activ-
ity (Figure 7). The results of this study showed that hypoxia can protect
cancer cells that express a functional p53 against chemotherapy by down-
regulating p53 at protein level. However, it seems that the regulation of
p53 by hypoxia is not sufficient to induce the resistance of hypoxic
tumoral cells against chemotherapy: a prosurvival pathway, for example,
triggered by c-jun activity, also needs to be upregulated.
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Figure W1. Effect of p53 siRNA on the p53 mRNA and protein levels. HepG2 cells were transfected with p53 siRNA or negative control
siRNA during 24 hours. Twenty-four hours after the end of the transfection, total RNA was extracted, submitted to reverse transcription,
and then to amplification in the presence of SYBR Green and specific primers (A). RPL13A was used as the housekeeping gene for data
normalization. At the same time, total protein extracts were prepared and were analyzed by Western blot analysis for p53 using a spe-
cific anti-p53 antibody (B). α-Tubulin was used to assess the total amount of proteins loaded on the gel.
Figure W2. Effect of Bak1 siRNA on the Bak1 mRNA and protein levels. HepG2 cells were transfected with Bak1 siRNA or negative
control siRNA during 24 hours. Eight hours later, cells were incubated with (Ne; 50 μM) or without etoposide (Nx) for 16 hours. At the
end of the incubation, total RNA was extracted, submitted to reverse transcription, and then to amplification in the presence of SYBR
Green and specific primers (A). RPL13A was used as the housekeeping gene for data normalization. At the same time, total protein ex-
tracts were prepared and were analyzed by Western blot analysis for Bak1 using a specific anti-Bak1 antibody (B). α-Tubulin was used to
assess the total amount of proteins loaded on the gel.
Figure W3. Effect of c-jun siRNA on the c-jun mRNA and protein levels. HepG2 cells were transfected with c-jun siRNA or negative control
siRNA during 24 hours. Eight hours later, cells were incubated under normoxic (Nx; 21%O2) or hypoxic (Hx; 1%O2) conditions with (Ne-He;
50 μM) or without etoposide (Nx-Hx) for 16 hours. At the end of the incubation, total RNA was extracted, submitted to reverse transcription,
and then to amplification in the presence of SYBR Green and specific primers (A). RPL13A was used as the housekeeping gene for data
normalization. At the same time, total protein extracts were prepared and were analyzed by Western blot analysis for c-jun using a specific
anti–c-jun antibody (B). α-Tubulin was used to assess the total amount of proteins loaded on the gel.
